Antiviral Cellular Therapy for Enhancing T-cell Reconstitution Before or After Hematopoietic Stem Cell Transplantation (ACES): a two-arm, open label phase II interventional trial of pediatric patients with risk factor assessment

Flow cytometry and TCR sequencing dataset from the ACES study (NCT03475212), a phase II multicenter consortium study for the treatment of pediatric patients with inborn errors of immunity and/or post allogeneic hematopoietic stem cell transplant with refractory viral infections using partially-HLA matched virus-specific T cells targeting cytomegalovirus, Epstein-Barr virus, or adenovirus.  Recipients of virus-specific T cell infusions were evaluated at multiple time points before and after infusion, with a focus on days 0, 14, 28, 45, and 90.  Recipient T cells were expanded in vitra against the targeted viruses for 10 days and then re-stimulated with viral peptide libraries (CMV pp65/IE1, EBV EBNA1/LMP2, Adenovirus hexon/penton) and evaluated by intracellular cytokine staining.   Staining of disparate HLA alleles between the VST donor and HSCT donor was included where possible.    T cell receptor beta chain sequencing was performed on availble virus-specific T cell (VST) products and recipient blood samples (bulk PBMCs or sorted T cells) in order to track virus-specific clonotypes.  Where possible, VSTs were stimulated with viral peptide libraries and sorted to isolate Interferon-gamma+ T cells for TCR sequencing of antigen-specific T cells.   T cell sequencing was performed using the Adaptive immunoseq platform as well as RNA-based TCR deep sequencing as previously described (PMID: 31219185)